Compare CBAT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBAT | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.5M | 79.9M |
| IPO Year | 2006 | 2020 |
| Metric | CBAT | PLRX |
|---|---|---|
| Price | $0.98 | $1.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | 249.9K | ★ 621.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 533.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,614,609.00 | N/A |
| Revenue This Year | $16.06 | N/A |
| Revenue Next Year | $70.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $1.09 |
| 52 Week High | $1.25 | $1.95 |
| Indicator | CBAT | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 59.36 |
| Support Level | $0.83 | $1.12 |
| Resistance Level | $1.06 | $1.36 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 68.18 | 90.70 |
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.